Lantern Pharma, Inc. (LTRN)
NASDAQ:LTRN
Want to see LTRN full AI Analyst Report?
LTRN Stock Chart & Stats
$3.02
$0.04(1.09%)
At close: 4:00 PM EST
$3.02
$0.04(1.09%)
Day’s Range― - ―
52-Week Range$1.11 - $5.74
Previous CloseN/A
Volume32.66K
Average Volume (3M)293.55K
Market Cap
$48.87M
Enterprise Value$44.77M
Total Cash (Recent Filing)$6.32M
Total Debt (Recent Filing)$59.08K
Price to Earnings (P/E)―
Beta2.33
Next Earnings
Aug 12, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.45
Shares Outstanding12,758,872
10 Day Avg. Volume223,536
30 Day Avg. Volume293,553
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)5.05
Price to Sales (P/S)0.00
P/FCF Ratio-2.11
Enterprise Value/Market Cap0.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-11.62K
Enterprise Value/Ebitda-2.82
Forecast
1Y Price Target
$25.00Price Target Upside727.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.57
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery low reported leverage gives Lantern financial flexibility typical for development-stage biotechs. With minimal interest burden, management can prioritize R&D and strategic transactions without immediate debt service pressure, improving ability to navigate multi-stage clinical development.
Planned WithZeta.ai SpinoffSpinning the withZeta.ai platform creates a structurally distinct business that can pursue software licensing and subscription revenue, attract dedicated investors, and enable focused capital allocation. This reduces single-asset dependency and can unlock strategic partnerships and clearer monetization paths over the medium term.
Clinical Pipeline ValidationMultiple regulatory and clinical milestones across assets (Phase 2 progress, IND clearance, orphan designation, positive early clinical signals) materially de-risk the pipeline. These durable achievements improve partner/sponsor attractiveness and heighten the odds of future licensing, collaborations, or milestone-driven value realization.
Bears Say
Sustained Negative Cash FlowPersistent and substantial cash burn means Lantern cannot self-fund development long term. Continued negative operating and free cash flow make the company dependent on capital markets or partners, increasing execution risk if financing terms worsen or if clinical timelines extend beyond planned runway.
Ongoing Financing / Dilution RiskFrequent equity financings and warrants indicate recurring funding needs; these mechanisms dilute existing shareholders and create financing overhang. Reliance on capital raises to sustain R&D increases vulnerability to market conditions and may constrain long-term returns absent clear partner deals or revenue generation.
No Product Revenue; Commercial Dependence On TrialsAs a clinical-stage company with no material product sales, Lantern’s business outcomes are binary and tied to trial success, regulatory approvals, or licensing. This structural lack of recurring revenue heightens reliance on successful clinical data and external partners to convert pipeline progress into sustainable cash flows.
Lantern Pharma News
LTRN FAQ
What was Lantern Pharma, Inc.’s price range in the past 12 months?
Lantern Pharma, Inc. lowest stock price was $1.11 and its highest was $5.74 in the past 12 months.
What is Lantern Pharma, Inc.’s market cap?
Lantern Pharma, Inc.’s market cap is $48.87M.
When is Lantern Pharma, Inc.’s upcoming earnings report date?
Lantern Pharma, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 48 days.
How were Lantern Pharma, Inc.’s earnings last quarter?
Lantern Pharma, Inc. released its earnings results on May 15, 2026. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.36 by $0.06.
Is Lantern Pharma, Inc. overvalued?
According to Wall Street analysts Lantern Pharma, Inc.’s price is currently Undervalued.
Does Lantern Pharma, Inc. pay dividends?
Lantern Pharma, Inc. does not currently pay dividends.
What is Lantern Pharma, Inc.’s EPS estimate?
Lantern Pharma, Inc.’s EPS estimate is -0.38.
How many shares outstanding does Lantern Pharma, Inc. have?
Lantern Pharma, Inc. has 12,758,872 shares outstanding.
What happened to Lantern Pharma, Inc.’s price movement after its last earnings report?
Lantern Pharma, Inc. reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.36. Following the earnings report the stock price went down -4.459%.
Which hedge fund is a major shareholder of Lantern Pharma, Inc.?
Currently, no hedge funds are holding shares in LTRN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lantern Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.00 (727.81% Upside)
$25.00 (727.81% Upside)
Hedge Fund Trend
Decreased
By 10.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $200.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
24.75%
12-Months-Change
Fundamentals
Return on Equity
-0.97%
Trailing 12-Months
Asset Growth
-65.76%
Trailing 12-Months
Company Description
Lantern Pharma, Inc.
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.
LTRN Company Deck
LTRN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements in clinical trial results and regulatory progress, along with advancements in AI platform commercialization. Financial stability was noted, but there is a requirement for additional funding in the near future.View all LTRN earnings summariesLTRN Stock 12 Month Forecast
Average Price Target
$25.00
▲(727.81% Upside)
Technical Analysis
Ownership Overview
1.12% Insiders
3.35% Mutual Funds
9.54% Other Institutional Investors
83.01% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---